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Background. Autosomal-recessive polycystic kidney disease
(ARPKD) is an important neonatal nephropathy characterized
by fusiform dilation of collecting ducts, congenital hepatic
fibrosis, and in some cases Caroli’s disease. The ARPKD gene,
PKHD1, has recently been identified. Herein we describe an
effective method for PKHD1 mutation screening and the results
from analysis of a novel ARPKD cohort.
Methods. The coding region of PKHD1 was amplified as 79
fragments and analyzed for base pair changes by denaturing high-
performance liquid chromatography (DHPLC). Forty-seven
ARPKD and 14 pedigrees with congenital hepatic fibrosis and/or
Caroli’s disease, were screened for PKHD1 mutations.
Results. Thirty-three different mutations were detected on
57 alleles (51.1% ARPKD, 32.1% congenital hepatic fibrosis/
Caroli’s disease). In the 22 pedigrees where both mutations were
identified, two were homozygous for 9689delA and the remain-
der were compound heterozygotes; a combination of truncat-
ing, missense and splicing changes. Patients with two truncating
mutations all died in the perinatal period. Two frequent trun-
cating mutations were identified: 9689delA (9 alleles) and
5896insA (8 alleles) plus some more common missense changes;
haplotype analysis indicated most were ancestral mutations.
Conclusion. DHPLC has been established as a rapid muta-
tion screening method for ARPKD. The mutation detection
rate was high in severely affected patients (85%), lower in those
with moderate ARPKD (41.9%), and low, but significant, in
adults with congenital hepatic fibrosis/Caroli’s disease (32.1%).
The prospects for gene-based diagnostics are complicated by
the large gene size, marked allelic heterogeneity, and clinical
diversity of the ARPKD phenotype. Identification of some
common mutations, especially in specific populations, will aid
mutation screening.
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Autosomal-recessive polycystic kidney disease (ARPKD,
OMIM 263200) is a severe, inherited disorder of the
kidney that typically presents in the neonatal period and
has an incidence of 1/20,000 [1]. The neonatal disease
is characterized by bilateral renal involvement consisting
of fusiform dilation of the collecting ducts, often leading
to massive kidney enlargement [1, 2]. Approximately
30% of patients die in the perinatal period with pulmo-
nary hypoplasia due to oligohydramnios [3, 4]. A less
precisely defined number of patients present in later
childhood or as adults and in these cases the major clini-
cal complication is often liver disease [5]. The liver
involvement consists of proliferation and dilatation of
the interlobular ducts and portal fibrosis (congenital he-
patic fibrosis) and, in some cases, focal dilatation of the
larger intrahepatic bile ducts (Caroli’s disease) [6, 7].
Linkage analysis in ARPKD families mapped the
gene, PKHD1, to chromosome region 6p21-cen [8], and
subsequently by genetic and physical mapping to a 1cM
interval [9–11]. These studies indicated that ARPKD is
genetically homogeneous [12] and have facilitated prena-
tal diagnosis with closely linked flanking markers [13].
Recently, through the analysis of a newly described ani-
mal model of ARPKD, the PCK rat, and a positional
cloning approach, the PKHD1 gene has been identified
and characterized [14, 15]. PKHD1 is a large gene, ex-
tending over a genomic region of472 kb, with 66 coding
exons and a transcript of 16,235 bp. The disease protein,
fibrocystin, is predicted to contain 4074 amino acids with
a molecular weight of 447 kD. The conserved domains
and predicted structure of fibrocystin suggest that it may
have a role as a receptor in collecting duct and biliary
differentiation [14].
In the two papers describing PKHD1, 29 different
mutations and a total of 40 mutant alleles were identified
[14, 15]. The majority of changes were missense (N 
17), but frameshifting insertions or deletions (N  9)
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and nonsense mutations (N  3) were also identified.
Most mutations were unique but five were found on
more than one allele, with two changes described four
times. All cases in which both mutations were described
(apart from one consanguineous family) were compound
heterozygotes and of these only one case with two trun-
cating mutations was described [15]. Typical patterns
were a truncating and missense (N 11) or two missense
mutations (N  5). In a significant proportion of cases
no mutation, or just one mutant allele, was identified.
Rapid and efficient mutation analysis of PKDH1
would allow gene-based diagnostics to be established
and serve the significant demand for prenatal diagnosis
in this neonatal disorder. At present, molecular diagnos-
tics is possible by linkage analysis only in families in
which DNA is available from an affected sib with a firm
ARPKD diagnosis, and the family structure allows the
disease haplotype to be defined [13]. Gene-based diag-
nostics could extend the number of informative families
and also allow a definitive diagnosis of ARPKD in cases
where the clinical data are equivocal. At present, confu-
sion can occur between ARPKD and early-onset cases
of ADPKD and other childhood causes of renal cysto-
genesis [13]. The significance of congenital hepatic fibro-
sis and/or Caroli’s disease, with minimal kidney disease,
is also not always clear in an older child or adult. Addi-
tionally, mutation studies will help to determine the phe-
notypic range of ARPKD and show the extent to which
the clinical variability is associated with specific geno-
types.
To allow efficient gene-based diagnostics, accurate,
rapid and cost-effective methods of mutation screening
are required. We describe here a mutation screen of the
entire coding region of PKHD1 using denaturing high-
performance liquid chromatography (DHPLC). This
method has proved to be an efficient and effective method
for detecting base pair mutations in large, multiexon
genes (like PKHD1), with typical detection levels70%
[16, 17]. This study shows the feasibility of mutation
screening in ARPKD and the challenges to establishing
routine gene-based diagnostics. During review of this
manuscript, another paper describing mutation screen-
ing of PKHD1 was published [18], characterizing 34
novel mutations. Comparison with this paper will be made
in the Results and Discussion sections.
METHODS
Details of the study cohort
The study was approved by the appropriate Institu-
tional Review Board or Ethics Committee and all partici-
pants gave informed consent. A family history and clini-
cal information was collected from all pedigrees. Patients
were diagnosed as ARPKD using established diagnostic
criteria [13]. Imaging showed enlarged echogenic kid-
neys with poor corticomedullary differentiation in neo-
nates and moderate renal enlargement with macroscopic
cysts and/or medullary sponge kidney in older patients.
Liver analysis in most cases demonstrated at least one
of the following: radiologically, intrahepatic bile duct
dilation or echogenic liver parenchyma; histologically,
congenital hepatic fibrosis or ductal plate malformation;
and clinically, portal hypertension. Parents were clini-
cally unaffected with negative imaging studies. For analy-
sis purposes, ARPKD was considered severe if the dis-
ease resulted in perinatal death, or moderate if the
patient survived the perinatal period or was diagnosed
later [18]. Patients with predominant liver disease were
diagnosed as adults with congenital hepatic fibrosis
and/or Caroli’s disease and minimal or no evidence of
renal disease. The families come from Spain (designated
OV, PRR or HEP), the United States (M), or United
Kingdom (P). The proband and all family members wish-
ing to participate gave a blood sample for DNA isolation.
Amplification of the PKHD1 gene by polymerase
chain reaction (PCR)
Genomic DNA was isolated from a peripheral blood
sample by standard methods. In a few perinatal cases,
the QIAmp DNA Mini Kit (QIAGEN, Inc., Valencia,
CA, USA) was used to extract genomic DNA from for-
malin-fixed paraffin-embedded kidney tissue blocks.
Briefly, three 20 m slices, obtained using a Biocut 2030
microtome (Leica Instruments, Bannockburn, IL, USA),
were dissolved in xylene to release the tissue, followed
by a 100% ethanol wash. The samples were digested
with proteinase K at 56C overnight and the DNA iso-
lated using the standard QIAmp DNA Kit extraction
protocol.
All coding exons of the PKHD1 gene were amplified
from genomic DNA as fragments of 150 to 370 bp. Prim-
ers were generally positioned in introns 25 to 30 bp from
the exon boundary, in order to detect mutations of the
canonic splice sites, but to minimize detection of non-
pathogenic intronic changes. Polymerase chain reaction
(PCR) was performed as previously reported [14, 17].
Briefly, 60 ng of genomic DNA was amplified in a mix
containing 6 pmol of each primer, 200 mol of each de-
oxynucleoside triphosphate (dNTP), 2.5 mmol/L MgCl2,
1 U of AmplitaqGold (Applied Biosystems, Foster City,
CA, USA) in the supplied buffer, in a total volume of
25 L. The amplification program consisted typically of
an initial denaturation at 94C for 2 minutes, followed
by 35 cycles at 94C for 30 seconds, 44 to 65C for 30
seconds, and 72C for 30 seconds, with a final extension at
72C for 10 minutes. This protocol was used for all exons
except 2 and 3, where a dimethyl sulfoxide (DMSO)-
based PCR buffer [19] (exon 2) and a hot start protocol
with a high annealing temperature (exon 3) was employed
due to persistent nonspecific amplification and primer
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dimerization. PCR primers and conditions are summa-
rized in Table 1. Heteroduplexes were generated by incu-
bating the PCR product for 5 minutes at 95C; cooling
to 65C, 0.1C per second; 30 minutes at 65C; and cooling
to 37C 0.1C per second and 10 minutes at 37C. This
analysis assumed that patients were compound heterozy-
gotes for mutations, as had previously largely been found
[14, 15]. To screen for homozygous changes, an equal
quantity of normal amplicon was added to the patient
product before heteroduplex formation.
Mutation analysis of the PKHD1 gene by DHPLC
DHPLC was performed using the Wave system (Trans-
genomic, Inc., Omaha, NE, USA) following the protocol
we described previously [14, 17]. Briefly, 300 to 600 ng
of crude PCR product was injected into the chromato-
graphic column (DNASep cartridge) (Transgenomic
Inc.) and eluted through a 8.6-minute linear gradient of
buffer A [5% triethylammonium acetate (TEAA)] and
buffer B (5% TEAA and 25% acetonitrile). A 2% buffer
B slope per minute was used. Melting profiles were ana-
lyzed using Wavemaker 4.0.32 software and each ampli-
con was run at the predicted melting temperature 1
and 2C (and additional temperatures when needed) to
optimize conditions. Due to the initial lack of positive
controls, a set of eight samples was used to test the analysis
conditions. The optimal temperature was considered to
be that immediately before a significant decrease in the
retention time (before 3 minutes) and/or excessive broad-
ening of the peak occurred, indicating excess denatur-
ation. This was typically located in the range of 50% to
75% helical fraction. When a sequence change was found,
that sample was used to refine the optimal analysis tem-
perature; when the best resolution of the mutant ampli-
con occurred. Where more than one positive control was
available, the most subtle change was chosen as an inter-
nal control. Samples showing an aberrant elution profile
were typically reamplified and subjected to direct se-
quencing as previously described [17]. The DHPLC con-
ditions and positive controls available for each amplicon
are summarized in Table 1.
Validation of mutations
Missense mutations and subtle splicing mutations were
validated through the analysis of 50 normal controls (100
normal chromosomes). This was performed using DHPLC
and including the candidate mutation for comparison
with the normal samples. Whenever DNA from other
members of the pedigree was available, validation was
also confirmed by family segregation analysis. This was
performed by DHPLC, or alternatively by direct se-
quencing when more than one sequence change was pres-
ent in the fragment being analyzed.
Restriction assays were developed to facilitate the de-
tection of the four most common mutations: 5895insA,
9689delA, T36M, and I222V. For the mutations T36M
and I222V, the same restriction enzyme was used, HpyCH4
IV (New England Biolabs, Beverly, MA, USA). For T36M,
the mutation abolishes a restriction site, so that the nor-
mal restriction pattern of exonic fragment 3 (54  52 
52 bp) is changed to 106 52 bp; for I222V, the mutation
creates a new restriction site and the exon 9 amplicon
(which is not cut by the enzyme) generates fragments of
102  55 bp. A restriction-generating PCR (RG-PCR)
approach was designed to detect 5896insA with a modi-
fied reverse primer (5-ACTTCACACACCTTTAATG
TGCACT-3; bold indicates base modified) and the for-
ward exon 36 oligonucleotide. The normal 206 bp frag-
ment was resolved as 179  28 bp in the mutant when
digested with Afl II (New England Biolabs). The restric-
tion enzyme HpyCH4 III (New England Biolabs) was
predicted to digest the mutant exon 58d amplicon as frag-
ments of 119 188 bp. However, we found this digestion
inconsistent and analyzed for homozygotes by DHPLC
with normal fragment added. Restriction digestions were
typically performed in a total volume of 20 L, using
10 L (1 g) PCR product and 10 to 20 units of restric-
tion enzyme in the supplied buffer and incubated at 37C
for 2 hours. Bovine serum albumin (BSA) (1%) was
added to Afl II. Restriction bands were visualized on
3% agarose gels after ethidium bromide staining.
Mutation positions are described using the PKHD1
cDNA sequence, AY074797, with the A of the start codon
designated as first nucleotide. The program SignalP 2.0
(http//www.cbs.dtn.dk/services/SignalP/) was used to ana-
lyze the consequence of the A17V mutation on cleavage
of the protein.
Haplotype analysis
Families with recurrent/ancestral mutations were ana-
lyzed with the intragenic microsatellite markers D6S1344
(IVS15) and D6S1714 (IVS60) using primers described
in Genbank and previously defined methods [20]. Briefly,
the markers were amplified by PCR, the products re-
solved on a 10% polyacylamide gel, stained with ethid-
ium bromide and visualized by ultraviolet transillumina-
tion. Marker segregation was analyzed to determine the
haplotype associated with the specific mutations. The nor-
mal frequency of haplotypes was calculated from the
normal chromosomes in the same families.
RESULTS
Development of a mutation screening strategy for PKHD1
The large size of the PKHD1 open reading frame
(12,222 bp) and multiple exon structure indicated that a
rapid semiautomated method for mutation screening was
required. Previously, we had successfully developed a
DHPLC method to screen the large, multiexon, ADPKD
gene PKD1 [17] and therefore adapted these methods to
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PKHD1. The 66 coding exons of PKHD1 were amplified
from genomic DNA as 79 PCR amplicons, ranging from
150 to 370 bp (see Table 1 for details), a size we had
previously found optimal for DHPLC analysis [17]. Most
exons were amplified as a single fragment but multiple
overlapping fragments were required for the larger exons
32, 58, 61, and 67 (see Table 1). To establish appropriate
conditions for DHPLC, each fragment was analyzed us-
ing the Wavemaker software and idealized conditions
determined empirically (see Methods section and Table 1
for details). Most amplicons were analyzed at a single
temperature but, because of different distinct melting
domains, 21 amplicons were analyzed at two different
temperatures (see Table 1 for details). Fragments that
generated an aberrant profile were sequenced to deter-
mine the DNA change and, if samples were available,
segregation was analyzed in the family. Changes pre-
dicted to truncate the protein and missense and splicing
changes that segregated with the disease (if analysis was
possible) and not found in 100 normal controls, were
considered to be mutations. An initial test of the screen-
ing system employed a small group of ARPKD patients
as part of the study to identify the disease gene [14];
characterizing 18 different mutations throughout PKHD1.
Mutation screening of a large novel cohort of
ARPKD and congenital hepatic fibrosis/Caroli’s
disease patients
To establish a clearer view of the types of mutations
associated with ARPKD, and the prospects for gene-
based diagnostics, a larger cohort of patients was ana-
lyzed. DNA samples were collected from Spanish, Amer-
ican, and British pedigrees. As the preliminary analysis
[14] indicated that PKHD1 mutations were found in
older patients with a primary diagnosis of congenital
hepatic fibrosis and/or Caroli’s disease, as well as typical
ARPKD, patients with a wide range of phenotypes were
analyzed (see Methods section for details). A total cohort
of 61 families was screened for mutations, 47 with a
primary diagnosis of ARPKD and 14 congenital hepatic
fibrosis and/or Caroli’s disease patients. In 56 cases,
DNA from the proband was analyzed and in the re-
maining five, where the patient died in the perinatal
period and no sample was available, DNA from the
parents was screened. Examples of mutant DHPLC pro-
files and segregation analysis are shown in Figure 1.
Details of the mutations identified in this cohort and the
clinical characteristics of these patients are shown in
Table 2. The positions of mutations are spread through-
out the gene (Fig. 2) and the mutation details of the
population are summarized in Table 3.

Fig. 2. The open reading frame of PKHD1 showing the location of mutations described in this study and our previously reported changes [14].
Mutations detected at least twice in this study are in bold and those described in previous studies underlined [14, 15, 18]. Mutations are color-
coded: green, missense; red, insertion/deletion; purple, splicing; and light blue, nonsense. *Missense mutations that may lead to aberrant splicing.
A total of 33 different mutations were characterized
on 57 mutant alleles; both mutations were identified in
22 families and one mutation in a further 13 (see Table
3 for details). Ten mutations were found on more than
one allele and two were particularly frequent, 9689delA
(9 alleles) and 5895insA (8 alleles). Three missense
changes, T2688K (5 alleles), T36M (4 alleles), and I222V
(3 alleles), were also common. Eight different insertion
or deletion mutations, predicted to cause a frame-shifting
change, were identified, accounting for 26 of the mutant
alleles, while 21 missense changes were found on 27
alleles. In addition, four potential intronic or exonic
splicing mutations were characterized. One, IVS28-
2A→C, is a clear splicing mutation but the remainder
are less clearly pathogenic but may change or create
splice sites: IVS33-9T→G, weakening the polypyrimid-
ine tract; IVS434A→T, lowering the strength of the
splice acceptor site; and 657C→T generating a potential
cryptic splice site, AAG/G(T)GACT, close to the end
of exon 9. Two of the missense mutations may also cause
aberrant splicing. We have previously described how
the conservative substitution, I222V, might cause cryptic
splicing at the end of exon 9 [14]. The A17V mutation
may also generate a cryptic splice site, TGG/G(T)AGGT,
4 bp 5 to the normal IVS2 splice site, resulting in a
frame-shifting change. All of these mechanisms have
been documented as mutagenic in other genes [21, 22],
but we have not proved that these changes disrupt splic-
ing herein as we have been unable to amplify the PKHD1
transcript from readily available sources of patient RNA.
A17V may also cause disease by disrupting cleavage of
the protein. This change is predicted to move the site of
cleavage of the signal peptide 4 residues C-terminal to
the sequence LSL-HI.
In the 22 pedigrees where both mutations were identi-
fied, 20 were compound heterozygotes. These consisted of
one with two truncating changes; 10 truncating and mis-
sense; five, two missense; three missense and splicing; and
one truncating and splicing (see Fig. 1 for examples and
Table 2 for details). The probands in families PRR-1 and
PRR-12 are predicted to be homozygous for 9689delA
(from analysis of the parental alleles) but patient mate-
rial was not available for confirmation. Restriction assays
were developed to rapidly screen for the four most com-
mon changes, 5895insA, 9689delA, T36M, and I222V
(see Methods section for details). Figure 1D shows how
this assay was used to trace T36M in pedigree OV-7. To
test whether other homozygous cases were missed by our
screening method for heteroduplexes, the four common
Fig. 1. Examples of mutation analysis by denaturing high-performance liquid chromatography (DHPLC) and tracing alleles in autosomal-recessive
polycystic kidney disease (ARPKD) families. Mutant heteroduplexes are visualized as an earlier elution peak or shoulder on the homoduplex
peak. In each case the affected individuals are compound heterozygotes for mutations inherited from both parents, consistent with a recessive disease.
Affected individuals are shown as filled shapes and carrier individuals, half filled. *Individuals with the mutation. (A ) Pedigree PRR-9 segregating
the mutations 6383delT and I222V. Material was not available from the proband’s affected brother (9F; Table 2) for analysis. (B ) I222V and
383delC segregate in family PRR-15. (C ) The proband in PRR-17 is a compound heterozygote for two truncating mutations, 3761CC→G and
9689delA. (D) The mutations T36M and IVS43 4A→T segregate in pedigree OV-7 with two affected children, 2537 (brother 2) and 2538 (brother 3).
The T36M change is traced using a restriction digest with the enzyme HpyCH4 IV (see Methods section for details).
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Table 3. Details of mutations in autosomal-recessive polycystic kidney disease (ARPKD) and congenital hepatic fibrosis (CHF) patient populations
Clinical phenotype
ARPKD
Population and mutation details Severe Moderate All CHF Total
Pedigreesa 10 (20) 37 (74) 47 (94) 14 (28) 61 (122)
Both mutations detectedb 7 (7) 11 (11) 18 (18) 4 (1) 22 (19)
Single mutation detectedc 3 (3) 9 (7) 12 (10) 1 (1) 13 (11)
Mutant allelesd 17 (85) 31 (41.9) 48 (51.1) 9 (32.1) 57 (46.7)
Mutant pedigreesd,e 10 (100) 20 (54.1) 30 (63.8) 5 (35.7) 35 (57.4)
Different mutations 12 17 29 8 33
Ancestral mutationsa,f 8 (14) 10 (22) 12 (36) 6 (7) 12 (41)
a ( ), Disease alleles
b ( ), Segregation demonstrated
c ( ), Parental origin known
d ( ), % of total
e At least one mutation detected
f Detected at least twice in this study or previously described [14, 15, 18]
Table 4. Haplotypes associated with ancestral mutations
Common haplotype marker
Totalallele sizes bp
mutant Mutant alleles with Normalb frequency
Mutation Exon D6S1344a D6S1714a alleles common haplotype of haplotype %
T36M 3 180 123 6 4c 0
383delC 5 168 127 2 2 22.5
I222V 9 172 127 4 4 5
1529delG 16 168 127 2 2 22.5
3761CC→G 32 168 127 2 2 22.5
5895insA 36 172 129 9 5 5
9689delA 58 176 127 9 5  4d 25
a D6S1344, IVS15; D6S1714, IVS60
b In 40 normal chromosomes
c All six have 180 bp D6S1344 allele
d Segregation not proven in four
mutations were analyzed by restriction assays, or by
DHPLC analysis after adding normal DNA. In addition,
the entire gene was screened by DHPLC with normal
DNA added in six mutation-negative patients, but nei-
ther of these methods identified any further homozygous
mutations. To test whether the recurrent mutations had
a common ancestral origin, the haplotype associated with
the mutation was determined with two intragenic mark-
ers, D6S1344 and D6S1714 (see Table 4). In all cases
(except T2869K), a common haplotype was found associ-
ated with the majority of mutant alleles, including all
alleles for four mutations, indicating that they are most
likely ancestral changes.
As well as the putative pathogenic changes we de-
tected a total of 34 polymorphic changes, 24 of which
are exonic (see Table 5 for details). These were defined as
polymorphisms because they were detected in the normal
population or did not segregate appropriately with the
disease phenotype. Several of the changes involve non-
conservative amino acid substitutions.
DISCUSSION
We have described a rapid and effective means to
screen for mutations in the PKHD1 gene. Although di-
rect sequencing may be the gold standard for mutation
detection in small genes [23], for large multiexon genes,
such as PKHD1, a semiautomated screening method is
required for cost-effective analysis [16, 18, 24]. A total
of 33 different mutations were identified, 26 of which
are newly described changes and both disease mutations
were characterized in 22 cases. This analysis gave a much
clearer view of the type and pattern of mutations associ-
ated with ARPKD, revealed some common changes, and
provided a hint of genotype/phenotype associations.
The overall disease allele detection rate of 57 of 122
(46.7%) is low compared to other large multiexon genes
that have been analyzed using similar methodologies,
where detection rates of 70% have typically been de-
scribed [16, 17, 24, 25] and lower than the rate of 61%
described in the recent screen of PKHD1 [18]. However,
if we subdivide our population into severe and moderate
ARPKD, as described by Bergmann et al [18] and sepa-
rate the congenital hepatic fibrosis/Caroli’s disease pa-
tient group (see Methods section for details), the detec-
tion levels in the two studies are similar. We identified
mutations on 85% and 41.9% of alleles in the severe and
moderate groups, respectively, (compared to 77% and
40% [18]). The detection level in the congenital hepatic
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Table 5. Details of polymorphisms found in the study population
Nucleotide
change/
amino acid Allele
Designation position Exon/IVS frequency Reference
IVS1-47C/T IVS1 40/128 Novel
IVS1-30insA IVS1 2/238 Novel
214C/T L72 4 19/128 Novel
234C/T D78 4 8/128 [14]
IVS719T/C IVS7 32/128 Novel
IVS1423G/T IVS14 1/238 Novel
1185T/C D395 15 2/128 Novel
1587T/C N529 17 8/128 [14]
2046A/C P682 21 21/128 Novel
2196C/T V732 22 1/238 Novel
R/C760 2278C/T 22 37/128 [14]
IVS2213T/G IVS22 16/128 Novel
IVS2350C/T IVS23 53/128 Novel
IVS2353A/G IVS23 14/128 Novel
N/S830 2489A/G 24 10/128 [18]
3537T/C N1179 30 2/238 Novel
3756G/C L1252 32 2/238 [14]
A/V1262 3785C/T 32 9/238 [14]
4920A/G V1640 32 3/238 [14]
L/F1709 5125C/T 32 1/338 Novel
IVS3242del4 IVS32 5/128 Novel
L/V1870 5608T/G 35 4/128 Novel
7587G/A G2529 48 33/128 [14]
7764A/G L2588 49 30/128 [14]
IVS53-32C/G IVS53 33/128 Novel
9237G/A A3079 58 33/128 [14]
D/Y3139 9415G/T 58 2/128 [14]
S/R3505 10515C/T 61 5/128 [14]
10521C/T H3507 61 5/128 [14]
IVS619A/G IVS61 5/128 Novel
11340T/C P3780 63 4/128 [14]
Q/R3899 11196A/G 66 37/128 [14]
V/I3960 11878G/A 67 3/238 [14]
Q/R4048 12143A/G 67 42/128 [14]
fibrosis/Caroli’s disease group was 32.1% and no compa-
rable group was present in the other study. Therefore,
the detection rates for comparable populations were
slightly higher in this study, but the number of patients
in the severe ARPKD group, in which PKHD1 muta-
tions were most frequently detected, was smaller.
The different levels of mutation detection in the vari-
ous phenotype groups (Table 3) [18] indicate that defin-
ing the clinical phenotype is critical. In the severe group,
where the ARPKD diagnosis is clear, the detection level
of 17 of 20 alleles, with at least one mutation identified
in all patients, compares favorably with other large multi-
exon genes. The level may be enhanced in this group
because many mutations appear to be exonic truncating
changes [18] (see below) and therefore readily detected
by the exonic screening method employed. The much
lower detection level in the moderate ARPKD group
suggest that this may in part be due to the inadvertent
inclusion of other childhood forms of cystic disease (such
as early onset, de novo cases of ADPKD) [2, 26]. This
suggestion is supported by the finding of no mutation
in 17 of 37 (45.9%) moderate ARPKD pedigrees. An
alternative explanation, although not supported by link-
age studies of ARPKD [12, 13], is that there is significant
genetic heterogeneity. Mutation analysis of a recently
identified PKHD1 homolog, PKHDL1, did not indicate
that it was associated with ARPKD [27]. Careful clinical
reassessment, linkage studies and mutation screening of
ADPKD and known nephronophithisis genes are now
required in the pedigrees in which no PKHD1 mutation
was identified.
The inclusion of 14 pedigrees where the major disease
manifestation is congenital hepatic fibrosis and/or Car-
oli’s disease, with minimal renal involvement, significantly
influenced the overall detection rate. We previously found
[14], and confirmed in this study with the identification
of mutations in five such families (see Tables 2 and 3),
that these predominant liver phenotypes can be associ-
ated with PKHD1 mutation. However, the rate of detec-
tion of mutant alleles (9 of 28) (32.1%), and patients with
at least one mutation (5 of 14) (35.7%), is lower than in
the more typical ARPKD population (see Table 3). So,
although PKHD1 can be associated with the later onset,
predominant congenital hepatic fibrosis/Caroli’s disease
phenotype, many of the patients in this population are
not due to mutation at this locus. It will now be important
to look at this population in light of the mutation data to
more precisely define the PKHD1 associated phenotype.
Other factors that may account for missed mutations
is the complexity of PKHD1 and, in particular, that mul-
tiple splice forms may be generated from this locus [14,
15, 28]. Consequently, additional exons may be present
that we have not screened, but which form parts of criti-
cal PKHD1 splice variants. Comparative analysis to mu-
rine Pkhd1 [29] and a greater understanding of the physio-
logic significance of the different splice forms will help to
identify other potential exons. The structure of PKHD1,
particularly the large introns, may also explain some of
the missed mutations. Changes in the introns, distant
from the splice donor and acceptor sites, which were not
analyzed in this study, may lead to aberrant splicing [22]
and be particularly important in the moderate ARPKD
group. Unfortunately, PKHD1 is not widely expressed
in material generally available from patients, (e.g., white
blood cells) and so it has not been possible to screen for
these cryptic splice event by analysis of RNA. Gross
DNA deletions may also be a significant form of muta-
tion, although we did not detect such changes in our
previous study by Southern blotting [14].
A problem that has been highlighted here is defining
what is a mutation in this disorder. The group of truncat-
ing and typical splicing mutations are clearly disease
associated. Missense changes that are frequently found
in ARPKD, segregate appropriately, change highly con-
served residues, and were not detected in the normal
population (such as T36M, I222V, and C3346R) can also
be fairly safely considered mutations [14, 15]. However,
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it is much less straightforward to categorize some of the
remaining missense changes and potential splice changes
situated distant from the canonic sequences. This was
evident in this study where in five patients three potential
mutations were identified and, using the mutation crite-
ria we defined of testing segregation and absence in the
normal population, we were unable to exclude one as a
polymorphism. One potential mutation, T2869K, illus-
trates the dilemma. It was present in several of these
pedigrees and, although this residue is not strongly con-
served (being valine in the mouse), it is a relatively non-
conservative change. Furthermore, it was not found in
our screen of normal chromosomes and present in sev-
eral ARPKD pedigrees. Another example of the uncer-
tainty is the change (D/Y3139) that we have defined as
a polymorphism (because of its presence in the normal
population) but was previously defined as a mutation
[15]. Of course, presence in the normal population is not
sufficient to exclude a change as a disease-associated
mutation in a recessive disorder, although given the esti-
mated carrier frequency (1 of 70 [13]) and the large
number of different mutations, the prevalence of any
individual mutation would be expected to be low in the
normal population. As data become available from more
studies, enrichment of a change in the ARPKD popula-
tion and segregation consistent with pathogenicity may
be the best evidence that it is disease associated. How-
ever, whether a change is a mutation or a polymorphism
may be something of a gray area in ARPKD, dependent
on what combination of alleles are found in an individual
or even the combination of changes on an allele. For
instance, if one allele is a hypomorphic missense muta-
tion, coinheritance of an inactivating change may be
sufficient to cause disease. Whereas, in combination with
another hypomorphic allele, that same mutation may
not cause disease, or the disease may be milder. A similar
situation with the R229Q mutation/polymorphism in
NPHS2 has recently been described in late-onset focal
segmental glomerulosclerosis [30]. The description of
further mutations and phenotype/genotype studies will
be required to resolve this uncertainty (see below).
An encouraging finding from a diagnostic viewpoint
is the detection of more common changes. The mutations
5895insA and 9689delA were found on eight and nine
alleles, respectively, and 5895insA was previously de-
scribed in six other cases [14, 15, 18]. Haplotype analysis
(Table 5) indicates that both are probably ancestral
rather than recurrent changes. Interestingly, a single hap-
lotype was likely found on all 9689delA alleles, whereas
the 5895insA haplotype was divergent on four of nine
alleles, probably due to recombination and marker muta-
tions, and indicating a more ancient origin. This is consis-
tent with finding 9689delA only in the Spanish popula-
tion, while 5895insA has been seen in different studies
and different populations [14, 15, 18]. Bergmann et al
[18] also described two ancestral mutations from the
Finnish population and a high level of the missense muta-
tion T36M. In the latter case, they suggested that it may
have arisen multiple times, as it is a cytosine to thymine
change at a CpG dinucleotide (sites of known enhanced
mutation [31]) and is associated with many different hap-
lotypes. However, our analysis of six T36M alleles identi-
fied a common haplotype on four and a shared rare allele
in all six cases (Table 5) with D6S1344 that lies close to
this mutation (25 kb). This data indicate a common
origin for many T36M alleles, but that the mutation
is relatively ancient and recombination has disrupted
haplotypes generated with more distant markers. A num-
ber of other mutations have been found several times
and in more than one study, I222V, 3761CC→G, and
I2957T, indicating that they may be relatively widespread
ancestral mutations [14, 15, 18]. Detection of one of these
characteristic mutations in a patient with an ARPKD-
like phenotype (even without finding the other mutation)
is now strong evidence that the patient has ARPKD.
The initial studies suggested that the combination of
mutations in ARPKD was unusual for a recessive disor-
der with only one homozygous case described (in a con-
sanguineous family), most were compound heterozygotes,
and only one pedigree had two truncating mutations
[14, 15]. The recent more extensive mutation screen has
described 19 homozygous cases, all from known consan-
guineous families or Finnish families homozygous for
the common Finnish mutation R496X, or T36M [18].
However, many different mutations (39) was also found
in that study and the present cohort largely reflects that
pattern (with 33 different mutations) and just two homo-
zygous cases, for the mutation 9689delA. The two homo-
zygous cases were not known to be from consanguineous
families and may reflect the relative high frequency of
the 9689delA mutation in Spain. The compound hetero-
zygotes were a combination of truncating and missense
(N  10), two missense (N  5), and other splicing
combinations (N 4). The variety of mutation combina-
tions and clinical variability of the disorder suggests that
phenotype/genotype correlation may be found and that
some missense mutations may by hypomorphic alleles.
Indeed, the three cases with two truncating mutations
in this study, and the 12 other similar cases that have
now been published [15, 18], have the severe form of
the disease with death in the perinatal period (Table 2).
However, it is worth noting that four other patients with
the severe phenotype in this study, and 17 other pub-
lished cases [18] (where both mutations have been identi-
fied) have a missense change on one or both alleles,
similar to the compound heterozygotes in the moderate
ARPKD group. Therefore, it will be important to collect
more families where both mutations are known and accu-
rately define the phenotype before genotype/phenotype
questions can be clearly answered. The wide range of
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different mutations also means that they will need to be
grouped by type and/or position to obtain statistically
significant data. This process will have to be done care-
fully as not all missense mutations are likely to have the
same effect on the protein (some may also cause aberrant
splicing) (see Table 2) and the position of the mutation
may be critical, with the variety of splice forms another
important variable.
Although many mutations have now been identified
in PKHD1 the prospects for gene-based diagnostics still
appear difficult. In particular, the relative low level of
mutation detection in moderate ARPKD patients and
clearly defining a PKHD1 mutation are problematic. Un-
doubtedly, the identification of more common mutations,
especially in particular populations, will aid molecular
diagnostics in those locations. As further mutations are
defined, and the identity of disease associated changes
and polymorphisms can be more clearly established, the
prospects for gene-based diagnostics will improve.
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